Assini JM - Search Results

1

Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance.

Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, St-Pierre P, Marette A, Huff MW. Mulvihill EE, et al. Among authors: assini jm. Diabetes. 2011 May;60(5):1446-57. doi: 10.2337/db10-0589. Epub 2011 Apr 6. Diabetes. 2011. PMID: 21471511 Free PMC article.

2

Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.

Mulvihill EE, Assini JM, Sutherland BG, DiMattia AS, Khami M, Koppes JB, Sawyez CG, Whitman SC, Huff MW. Mulvihill EE, et al. Among authors: assini jm. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):742-8. doi: 10.1161/ATVBAHA.109.201095. Epub 2010 Jan 28. Arterioscler Thromb Vasc Biol. 2010. PMID: 20110573

3

Citrus flavonoids and lipid metabolism.

Assini JM, Mulvihill EE, Huff MW. Assini JM, et al. Curr Opin Lipidol. 2013 Feb;24(1):34-40. doi: 10.1097/MOL.0b013e32835c07fd. Curr Opin Lipidol. 2013. PMID: 23254473 Review.

4

Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.

Assini JM, Mulvihill EE, Sutherland BG, Telford DE, Sawyez CG, Felder SL, Chhoker S, Edwards JY, Gros R, Huff MW. Assini JM, et al. J Lipid Res. 2013 Mar;54(3):711-724. doi: 10.1194/jlr.M032631. Epub 2012 Dec 26. J Lipid Res. 2013. PMID: 23269394 Free PMC article.

5

Gene therapy for hypercholesterolemia: sweet dreams and flying machines.

Huff MW, Assini JM, Hegele RA. Huff MW, et al. Among authors: assini jm. Circ Res. 2014 Aug 29;115(6):542-5. doi: 10.1161/CIRCRESAHA.114.304800. Circ Res. 2014. PMID: 25170090 No abstract available.

6

Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.

Assini JM, Mulvihill EE, Burke AC, Sutherland BG, Telford DE, Chhoker SS, Sawyez CG, Drangova M, Adams AC, Kharitonenkov A, Pin CL, Huff MW. Assini JM, et al. Endocrinology. 2015 Jun;156(6):2087-102. doi: 10.1210/en.2014-2003. Epub 2015 Mar 16. Endocrinology. 2015. PMID: 25774553

7

High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner.

Assini JM, Clark JR, Youssef A, Xing C, Doerfler AM, Park SH, Saxena L, Yaseen AB, Børen J, Gros R, Bao G, Lagor WR, Boffa MB, Koschinsky ML. Assini JM, et al. Atherosclerosis. 2023 Nov;384:117150. doi: 10.1016/j.atherosclerosis.2023.05.019. Epub 2023 May 30. Atherosclerosis. 2023. PMID: 37290980

8

Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages.

Lorey MB, Youssef A, Äikäs L, Borrelli M, Hermansson M, Assini JM, Kemppainen A, Ruhanen H, Ruuth M, Matikainen S, Kovanen PT, Käkelä R, Boffa MB, Koschinsky ML, Öörni K. Lorey MB, et al. Among authors: assini jm. Front Cardiovasc Med. 2023 May 24;10:1130162. doi: 10.3389/fcvm.2023.1130162. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37293282 Free PMC article.

9

LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study.

Doerfler AM, Park SH, Assini JM, Youssef A, Saxena L, Yaseen AB, De Giorgi M, Chuecos M, Hurley AE, Li A, Marcovina SM, Bao G, Boffa MB, Koschinsky ML, Lagor WR. Doerfler AM, et al. Among authors: assini jm. Mol Ther Methods Clin Dev. 2022 Oct 13;27:337-351. doi: 10.1016/j.omtm.2022.10.009. eCollection 2022 Dec 8. Mol Ther Methods Clin Dev. 2022. PMID: 36381302 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page